Gyon Technologies Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Gyon Technologies Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-26,399	Closed	-$284K	–	444
2022 Q2	$284K	Buy	+26,399	New	+$217K	0.08%	279
2022 Q1	–	Sell	-99,506	Closed	-$1.15M	–	376
2021 Q4	$1.15M	Buy	99,506 +77,573	+354%	+$865K	0.21%	138
2021 Q3	$209K	Buy	+21,933	New	+$224K	0.06%	350
2020 Q1	–	Sell	-11,252	Closed	-$110K	–	137
2019 Q4	$110K	Buy	+11,252	New	+$103K	0.07%	126

Other funds holding FOLD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Gyon Technologies Capital Management's FOLD Position: Q3 2022 in Review

Gyon Technologies Capital Management sold out of Amicus Therapeutics (FOLD) in Q3 2022, closing a stake of 26,399 shares — an estimated $284K sold.

Gyon Technologies Capital Management first reported a position in FOLD in Q4 2019 and held it in 4 quarters. The position peaked at $1.15M in Q4 2021. 222 funds tracked by Wall St. Rank hold FOLD as of Q3 2022.

Gyon Technologies Capital Management reported no remaining Amicus Therapeutics position as of Q3 2022 after selling out during the quarter.
Gyon Technologies Capital Management sold 26,399 Amicus Therapeutics shares in Q3 2022, an estimated $284K.
Gyon Technologies Capital Management first reported a position in Amicus Therapeutics in Q4 2019 and held it in 4 quarters.
Gyon Technologies Capital Management's Amicus Therapeutics position peaked at $1.15M in Q4 2021.
222 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.